These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29735936)

  • 21. Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats.
    Antipova V; Wree A; Holzmann C; Mann T; Palomero-Gallagher N; Zilles K; Schmitt O; Hawlitschka A
    Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30018211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis.
    Samotus O; Lee J; Jog M
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33917695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
    Stenslik MJ; Potts LF; Sonne JW; Cass WA; Turchan-Cholewo J; Pomerleau F; Huettl P; Ai Y; Gash DM; Gerhardt GA; Bradley LH
    J Neurosci Methods; 2015 Aug; 251():120-9. PubMed ID: 25999268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease.
    Sławek J; Madaliński M
    Int Rev Neurobiol; 2017; 134():1111-1142. PubMed ID: 28805566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
    Triadafilopoulos G; Gandhy R; Barlow C
    Parkinsonism Relat Disord; 2017 Nov; 44():33-37. PubMed ID: 28847681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distribution of Cleaved SNAP-25 in the Rat Brain, following Unilateral Injection of Botulinum Neurotoxin-A into the Striatum.
    Schümann F; Schmitt O; Wree A; Hawlitschka A
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.
    Mitchell SD; Sidiropoulos C
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33808714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection.
    Mann T; Zilles K; Klawitter F; Cremer M; Hawlitschka A; Palomero-Gallagher N; Schmitt O; Wree A
    Front Neuroanat; 2018; 12():65. PubMed ID: 30147647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
    eNeuro; 2017; 4(1):. PubMed ID: 28303260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrastriatal infusion of the Parkinsonian neurotoxin, MPP(+), induces damage of striatal cell nuclei in Sprague-Dawley rats.
    Banerjee R; Sreetama S; Saravanan KS; Chandra G; Nath De S; Mohanakumar KP
    J Chem Neuroanat; 2006 Dec; 32(2-4):90-100. PubMed ID: 16822645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
    Schulte-Mattler WJ
    CNS Drugs; 2008; 22(9):725-38. PubMed ID: 18698873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolution of botulinum neurotoxin type A for cosmetic applications.
    Carruthers J; Carruthers A
    J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of therapy effects by botulinum neurotoxin].
    Alajbegović A; Alajbegović S; Resić H
    Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of botulinum toxin in pregnancy and its impact on female reproductive health.
    Li W; Tang M
    Expert Opin Drug Saf; 2020 Jan; 19(1):83-91. PubMed ID: 31868020
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
    Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP
    Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906
    [No Abstract]   [Full Text] [Related]  

  • 40. Lingual protrusion dystonia: Manifestation during "on" periods in Parkinson's disease.
    Maiola R; Ramirez Gómez CC; Micheli F
    J Neurol Sci; 2016 Nov; 370():256-257. PubMed ID: 27772770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.